FDA approves Novartis’ Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.
Importance Rank:
1
FDA approves Novartis’ Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.